
Caribou Biosciences (CRBU) Stock Forecast & Price Target
Caribou Biosciences (CRBU) Analyst Ratings
Bulls say
Caribou Biosciences is expected to continue to see improvements in their financial results, with a net loss of $0.26 per share in 1Q26 compared to a previously estimated net loss of $0.32 per share. They also have a healthy balance sheet with $118.6M in cash, cash equivalents, and marketable securities, providing a strong runway into the second half of 2027. Additionally, the company's discounted cash flow valuation, combined with a high probability of approval for their lead assets, CB-010 and CB-011, leads to a positive outlook for their future growth potential. However, there are some risks to consider, such as the potential for negative clinical results or delays in advancing candidates into registrational programs.
Bears say
Caribou Biosciences is facing significant challenges in its CRISPR genome-editing technology and has reported a negative net income of $28.7 million for the second quarter of 2021. The company has also reported a decrease in its collaboration revenue from $4.1 million in the second quarter of 2020 to $0.7 million in the same period of 2021. Additionally, the company is heavily reliant on the United States for revenue, which exposes it to potential regulatory hurdles and market volatility.
This aggregate rating is based on analysts' research of Caribou Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Caribou Biosciences (CRBU) Analyst Forecast & Price Prediction
Start investing in Caribou Biosciences (CRBU)
Order type
Buy in
Order amount
Est. shares
0 shares